Abstract
Introduction
Pulmonary arterial hypertension (PAH) is a hemodynamic and pathophysiological condition with multiple etiologies characterized by chronic and progressive remodelling of small pulmonary arteries, resulting in increased pulmonary vascular resistance (PVR) (1) . Evidence suggests that inflammation, nitrogen oxides and oxidative stress contribute to the development and progression of lesions in the pulmonary vasculature (2, 3) . The reactive oxygen species (ROS) are an important mediator of vascular tonus, their excess generation being involved in the pathogenesis of PAH (4, 5) . Despite recent therapeutic advances in PAH which targets the three major pathophysiological pathways: the endothelin pathway, the prostacyclin pathway and the nitric oxide pathway, the evolution of many patients with PAH is progressive (1, (6) (7) (8) .
The role of genetics in PAH, both the risk of developing the disease and the progression of pulmonary vascular lesions, has been proven (9) (10) (11) (12) (13) (14) . The human multidrug resistance gene (MDR1) (or ABCB1) encodes an integrated membrane protein, P-glycoprotein (Pgp), which plays an important role in the bioavailability of some drug agents and also in the protection of cells against toxic substances and metabolites by acting ATP-dependent cellular efflux mechanism (15) . P-glycoprotein is expressed in the epithelial cells of different organs, including the lungs, where it facilitates transmembrane intracellular transport of various toxins, decreasing the intracellular concentration of toxic compounds (12, 16) . MDR1 polymorphism is associated with the decrease synthesis and function alteration of P-gp. From more than 50 single nucleotide MDR1 polymorphisms, MDR C3435T, MDR C1236T and MDR G2677T polymorphisms are the most extensively studied (17) (18) (19) (20) (21) (22) .
MDR1 polymorphism could not be associated with the effectiveness of pulmonary vasodilator therapy because endothelin receptor antagonists and phosphodiesterase type 5 inhibitors are not substrate for P-gp. However, the MDR1 polymorphism, lowering expression of the P-gp in the pulmonary tissue, may be involved in the progression of PAH by affecting cellular protection against the deleterious action of ROS (23) . The aim of our study is to determine the relevance of MDR1 polymorphism in the pediatric PAH clinical course.
Material and Methods
This is a prospective case-control study in which we assess three polymorphisms in MDR1 gene: G2677T, C1236T and C3435T in PAH patients and in age-and sex-matched healthy children. The study protocol was approved by the local Ethics Committee of the University of Medicine and Pharmacy of Tirgu Mures. A written informed consent was obtained from the parents of all the children included in study.
Study population. A total of 40 consecutive pediatric patients with PAH (median age of 9.75 ± 4.38 years), treated in the largest pediatric PAH Centre in Romania, were evaluated in this prospective longitudinal, non-interventional study. PAH was defined in accordance with 2015 ESC/ ERS Guidelines as an increase in mean pulmonary arterial pressure ≥ 25mmHg at rest as assessed by right heart catheterization, a pulmonary artery wedge pressure (PAWP) ≤ 15mmHg, and a PVR >3 Wood units in the absence of any other causes of precapillary PAH (24) . Exclusion criteria: Patients older than 18 years and those with pulmonary hypertension due to left heart disease.
PAH etiology was secondary to congenital heart defects (PAH-CHD) in 36 children (90%) and idiopathic (IPAH) in 4 children (10%). Echocardiography was performed in all children with an iE33 (Philips Medical Systems, Best, Netherlands) ultrasound machine. Patients underwent a complete physical examination, assessment of WHO functional class (WHO FC) and assessment of exercise capacity, estimated with the 6-minute walking test (6MWT) in children ≥5 years. The 6MWT was performed using standard protocol as American Thoracic Society (ATS) guideline (25) . Patients were treated with specific vasodilator therapy in accordance with the current guidelines recommendation (24) .
Further, the patients were divided into 2 groups, according to their evolution after 12 months of follow-up: non-worsening group, consists of patients who remained clinically stable at 12-months (n= 28.70%) and worsening group, consists of patients who presented clinical worsening at 12-months due to progressive RV failure (n= 12.30%). Clinical worsening was defined as an increase in WHO FC with at least one class.
Forty age-and sex-matched healthy children, with no heart defects or pulmonary hypertension referred to the pediatricians for routine evaluation or flu were included in the study as controls ( Table 1) .
Genotyping
Genotyping was performed in all PAH patients and controls included in the study. Genomic DNA, isolated from fresh blood obtained from children included in the present research was genotyped for MDR1 (or ABCB1) gene polymorphisms as follows: C1236T, G2677T and C3435T. The genotypes of the investigated MDR1 gene, namely C1236T, G2677T and C3435T gene polymorphisms were established by using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis as previously described by Dong et al and corresponding FastDigest restriction enzyme (namely FastDigest EcoO109I, FastDigest BshNI, FastDigest MboI) supplied by ThermoFisher Scientific. The PCR conditions were similar to those reported previously (26, 27) Statistical analysis Statistical analysis was performed by Graph Pad InStat software (version 3.0). package program. All data were given as mean ± standard deviation (SD). Student's t-test was used to compare the parametric variables. Chi-square test (or Fisher exact test when appropriate) was used for the comparison of the frequency distribution of genotypes and alleles between PAH patients and controls and also between worsening and non-worsening PAH groups. P values < 0.05 were considered as statistically significant. Table 2 summarizes the genotype distributions and allele frequencies of the MDR1 C1236T, MDR1 G2677T and MDR1 C3435T polymorphisms in PAH group and control children. There were no significant differences in frequency distribution of the three studied genotypes or alleles between PAH patients and control children. Data are presented as means ± SD or no (%) CHD, congenital heart defects; PAH, pulmonary arterial hypertension; y, year
Results

MDR1 SNPs genotypes and alleles in PAH children and control group
MDR1 SNPs genotypes and alleles in PAH subgroups: worsening versus non-worsening
In terms of G2677T, C3435T and C1236T SNPs, we found no differences in the frequency distribution of genotypes and alleles between PAH children with clinical worsening and non-worsening (Table 3) . Also, when the synergic effects of two or three SNPs in different combination were assessed, we found no significant differences in these two groups.
Discussions
Although the progress in understanding of PAH pathophysiology has increased significantly in recent years, the prognosis of PAH remains unfavourable. Efforts are being made to investigate new genetic and molecular mechanisms involved in the pathogenesis of this progressively devastating disease.
MDR1 gene polymorphism, associated with the decrease of synthesis and alteration of P-gp function, has been associated with many pathologies in which it modifies the pharmacokinetics of therapeutic agents (26, 28, 29) . Pulmonary vasodilator therapy (endothelin receptor antagonists and phosphodiesterase type 5 inhibitors) does not act as an exogenous inducer of P-gp expression, which is why MDR1 polymorphism could not be associated with the efficiency of specific PAH treatment.
On the other hand, P-gp facilitates transmembrane intracellular transport of various toxins, de- creasing the intracellular concentration of toxic compounds (16) . The role of inflammation and oxidative stress in PAH pathogenesis is supported by many studies (3) (4) (5) (30) (31) (32) . Cytokines, growth factors and shear stress represent endogenous activators of NADPH (nicotinamide adenine dinucleotide phosphate oxidase), which is a molecular complex that generates ROS (2). MDR1 polymorphism, associated with decreased P-gp expression, may be involved in the pathogenesis and progression of PAH by affecting cellular protection against deleterious action of ROS (23) . The C1236T, G2677T and C3435T polymorphisms are the most studied single nucleotide MDR1 polymorphisms, previous investigations demonstrating the association of MDR1 polymorphism with many diseases (17, 23, 29, (33) (34) (35) (36) (37) . Manduz S et al, starting from the idea that MDR1 polymorphism plays a role in the inflammatory process and in the protection against oxidative stress, suggested that T alleles of the MDR1 C3435T gene are associated with abdominal aortic aneurysm (17). Wartenberg M. et al have associated the risk of spheroidal prostate cancer with the intrinsic decrease in P-gp expression by ROS (29). Ma L. et al concluded that MDR1 C1236T polymorphism may contribute to the susceptibility to chronic myeloid leukemia (41) . The current study did not identify any association between MDR1 C1236T, MDR1 G2677T and MDR1 C3435T polymorphisms (separately or in combination) and PAH in child population. Furthermore, these three MDR1 gene single nucleotide polymorphisms could not be correlated with the clinical worsening of pediatric PAH patients.
Pediatric PAH is a relative rare condition. Study data from the Netherlands have revealed a point prevalence of 4.4 for IPAH and 15.6 for CHD-PAH cases per million children (42) . Considering that almost two-thirds of the Romanian pediatric PAH cases (40 out of 64) are treated and followed-up in the Centre where the present study was carried out, and the Romanian child population is up to 4.4 million, we estimate that there is a reliable number of patients enrolled in this study. This is the first study to evaluate the role of MDR1 polymorphism in the clinical course of pediatric PAH patients. Lack of association between MDR1 SNPs and PAH may be explained by the existence of numerous MDR1 polymorphisms (about 50) that could be analyzed. Future genetic studies that evaluate inflammation and oxidative stress in PAH pathogenesis are needed to elucidate the genetic and molecular mechanisms involved in PAH progression. A better understanding of these mechanisms would lead to management optimization of patients with PAH and to the development of new therapeutic strategies.
Conclusion
MDR1 C1236T, MDR1 G2677T and MDR1 C3435T polymorphisms could not be correlated with the clinical evolution of pediatric PAH patients in our study.
